Weekly Clinical Updates

Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022 | Reinfections with Different SARS-CoV-2 Omicron Subvariants, France (CDC) | In adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality | Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022 | Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants | Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

Progress Toward Poliomyelitis Eradication — Pakistan, January 2021–July 2022 | Polio by the Numbers—A Global Perspective | Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV Seropositive Children 12–24 Months | Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022 | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

Adverse Childhood Experiences During the COVID-19 Pandemic and Associations with Poor Mental Health and Suicidal Behaviors Among High School Students | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales | Successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials | Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic

A healthcare-associated infection with Monkeypox virus of a healthcare worker during the 2022 outbreak | Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomized ascending dose phase I trial | Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment | Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study

Possible Occupational Infection of Healthcare Workers with Monkeypox Virus, Brazil | Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants | Rates of Monkeypox Cases by Vaccination Status | Paxlovid Significantly Reduces COVID-19 Hospitalizations and Deaths | Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19

Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68 — United States, July–September 2022 | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | Long Covid—An Update for Primary Care | A distinct symptom pattern emerges for COVID-19 long-haul: A Nationwide Study | SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain | Breakthrough Infection by SARS-CoV-2 Delta and Omicron Variants Elicited Immune Response Comparable to mRNA Booster Vaccination